【摘要】 目的:建立一株高特异性抗人脊索瘤单克隆抗体的杂交瘤细胞系,检测其在人脊索瘤组织中及其它骨肿瘤中的特异结合程度。方法:以人脊索瘤细胞株CM-319为抗原,免疫BALB/C小鼠,利用杂交瘤技术,研制出一株MAb-6F2杂交瘤细胞系。通过免疫组织化学方法检测了MAb-6F2在4种不同骨肿瘤石蜡切片和人正常髓核组织上的结合反应。结果:MAb-6F2在骨肉瘤组织上的结合率仅为10%;在软骨肉瘤上的结合率为10%;在骨样骨瘤组织上的结合率为10%;在脊索瘤组织上的结合率为100%;在正常髓核组织上为阴性;MAb-6F2在脊索瘤组织上的结合反应显著高于其它骨肿瘤(P<0.01)。结论:MAb-6F2在人脊索瘤组织中的特异性高结合,可以为脊索瘤的诊断提供新的手段。更多还原

【Abstract】 Objective:To establish a hybridoma cell line secreting anti-chordoma monoclonal antibody,and study its binding reactivity in human chordoma and other bone tumor tissues.Methods:Using hybridoma technology,to prepare MAb-6F2 hybridoma cell line through immuning BALB/C mouse with human chordoma cell line CM-319.Then the binding reactivity of MAb-6F2 was detected with immunohistochemistry in four different bone tumor paraffin sections and normal nucleus pulposus tissues.Results:The Binding rate of MAb-6F2 was 10% in osteosarcoma tissue,10% in chondrosarcoma tissue,10% in osteoid osteoma tissue,and negative in normal nucleus pulposus tissue,but 100% in chordoma tissue.The binding reactivity of MAb-6F2 in chordoma tissue was significantly higher than in other bone tumors(P < 0.01).Conclusion:MAb-6F2 could react in chordoma tissue specially,would have prospective application in the early diagnosis of human chordoma.更多还原